Shots:
- The EMA has received MAA of relacorilant for the treatment of Pt-resistant ovarian cancer
- MAA was supported by P-III (ROSELLA) & P-II trials, where relacorilant + nab-paclitaxel demonstrated improved PFS & OS compared to nab-paclitaxel monotx., with no need for biomarker selection & showed favorable safety
- Relacorilant (PO) is a GR antagonist that is also under the FDA’s review, with PDUFA data of Dec 30, 2025, for hypercortisolism & PDUFA of Jul 11, 2026, for Pt-resistant ovarian cancer
Ref: Corcept Therapeutics | Image: Corcept Therapeutics | Press Release
Related News:- Corcept Therapeutics Reports the US FDA’s NDA Acceptance of Relacorilant to Treat Platinum-Resistant Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
